single10MG
SNAP-8
10MG Protocol
SNAP-8 10MG
Injection Freq.
Inject once daily
Cycle Sched.
8–12 weeks; optional extension to 16 weeks
Reconstitution
3.0 mL BAC water
Reduction in wrinkle depth (average ~35%
up to ~60% in certain areas) reported in topical studies
Reduced eye-wrinkle appearance and improved skin elasticity in a microneedle-patch trial
Smoothing of expression lines reported in a multi-peptide serum study
Generally well tolerated
no unwanted systemic muscle weakness reported
1
Reconstitution Requirements
- 3.0 mL BAC water
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–4 | 330 mcg (0.33 mg) | 10 |
| 2 | Weeks 5–8 | 500 mcg (0.50 mg) | 15 |
| 3 | Weeks 9–12 | 1,000 mcg (1.0 mg) | 30 |
| 4 | Weeks 13–16 | 1,000 mcg (1.0 mg) | 30 |
Inject once daily
8–12 weeks; optional extension to 16 weeks
SNAP-8 is described as an extended analog of Argireline designed to mimic and competitively inhibit SNAP-25 activity within the SNARE complex, a key component of neurotransmitter release. By interfering with SNAP-25’s role in vesicle fusion, SNAP-8 reduces acetylcholine release at neuromuscular junctions, producing gentle muscle relaxation. The protocol contrasts this mechanism with botulinum toxin, which cleaves SNAP-25 and can cause paralysis; SNAP-8 is presented as a milder, non-paralyzing approach that aims to preserve natural facial expression while softening expression-line formation. Preclinical and formulation data summarized by the page suggest greater activity than Argireline in reducing neurotransmitter release and improved stability. The result is positioned as a cosmetic-focused mechanism: reducing muscle-contraction signaling that contributes to dynamic wrinkles, thereby supporting smoother appearance over several weeks of consistent application or administration.
Mild injection-site reactions (temporary redness/swelling/soreness)
No systemic toxicity reported at typical doses on page
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)